WO2020045983A1 - 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물 - Google Patents
유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물 Download PDFInfo
- Publication number
- WO2020045983A1 WO2020045983A1 PCT/KR2019/011001 KR2019011001W WO2020045983A1 WO 2020045983 A1 WO2020045983 A1 WO 2020045983A1 KR 2019011001 W KR2019011001 W KR 2019011001W WO 2020045983 A1 WO2020045983 A1 WO 2020045983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanocapsules
- emulsion
- emulsion composition
- composition
- water
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
Definitions
- nanocapsules forming emulsion particles and an emulsion composition comprising the same.
- the general emulsification technique is a method using a surfactant, and the other most known method is to control the physical properties of the particles, such as silica particles or some powder particles, the particles of Janus structure having both hydrophilic and lipophilic properties at the interface How to stabilize.
- this method shows a disadvantage in formulation stability due to freezing and thawing, and exhibits a limited usability to the unique finishing properties according to the powder particle characteristics used.
- the mass production of powder of Janus structure still has a number of technical limitations.
- PEG polyethylene glycol
- the present disclosure aims to provide an emulsion composition for forming emulsion particles into water-dispersible aprotic nanocapsules without the use of surfactants.
- Pickering emulsion is a method of emulsifying using powder, but the physical properties of the powder must be modified to amphiphilic, whereas the water-dispersion-type amphiphilic nanocapsules according to the present specification do not need other physical treatments and are stably present on the interface between water and oil. To form emulsified particles.
- an object of the present disclosure is to provide a method for preparing the emulsion composition.
- the techniques disclosed herein include a water phase; And an oil phase, wherein a plurality of aphiphilic nanocapsules are disposed at an interface between the aqueous phase and the oil phase, and an emulsified composition having emulsified particles formed by the plurality of aprotic nanocapsules is formed.
- the emulsion composition may be of oil-in-water type.
- the emulsion composition may be freezing at a temperature of less than -60 °C and then reduced pressure to sublimate and remove the water to prepare a dry product does not appear oil separation phenomenon.
- the aprotic nanocapsules may have an average particle size of 10 nm to 1 ⁇ m.
- the emulsified particles may be one having an average particle size of 1 ⁇ m to 30 ⁇ m.
- the aprotic nanocapsule is selected from the group consisting of liposomes, polymersomes, nanoemulsion particles, and solid lipid nanoparticles (SLN). It may be one or more.
- the aprotic nanocapsules may include one or more selected from the group consisting of phospholipids, waxes, butters, and ceramides.
- the aprotic nanocapsule may be included in the aqueous phase of the emulsion composition in a form dispersed in an aqueous dispersion.
- the emulsion composition may be a mixed weight ratio of the oil dispersion: an aqueous dispersion including an amphiphilic nanocapsule 1: 0.4 to 3.
- the aqueous dispersion containing the aprotic nanocapsules may include water, a polyhydric alcohol and a lipid.
- the lipid may be one or more selected from the group consisting of phospholipids, waxes, butters and ceramides.
- the technology disclosed herein is a method for preparing the emulsion composition, comprising the steps of mixing an aqueous phase and an oil phase comprising a water-dispersible aprotic nanocapsules; And it provides a method for producing an emulsion composition comprising the step of forming the emulsion particles surrounded by the aprotic nanocapsules.
- the technique disclosed herein has the effect of providing an emulsified composition that forms emulsified particles with water-dispersible aprotic nanocapsules without the use of surfactants.
- water-dispersible nanocapsules have been mainly used for the purpose of skin delivery or stabilization of efficacy ingredients, but the emulsion composition according to the present specification uses the water-dispersible nanocapsules for emulsification of the emulsion composition without modification of additional physical properties to form emulsion particles.
- the emulsion composition according to the present disclosure is capable of forming emulsion particles in an oil-in-water emulsion composition without using a surfactant.
- the technology disclosed herein has the effect of providing a method for producing the emulsion composition.
- FIG. 1A shows a polarization microscope image of an emulsion composition according to one embodiment of the present specification.
- FIG. 1B shows a confocal microscope image of an emulsion composition according to one embodiment of the present disclosure.
- Figure 2 shows a comparison of the rheological measurement of the emulsion composition according to an embodiment of the present disclosure and conventional O / W emulsion and pickling emulsion.
- the graph shows the pickling emulsion, the O / W emulsion, the composition of Example 11 and the composition of Example 2 in order from top to bottom.
- Figure 3 shows the results of confirming the skin texture changes when applying the emulsion composition according to an embodiment of the present disclosure on the skin.
- Figure 4 shows the moisture content change rate (%) by checking the skin moisture content change when applying the emulsion composition according to an embodiment of the present disclosure on the skin.
- Figure 5 shows the results of confirming the formulation stability after lyophilization of the emulsion composition and conventional O / W emulsion according to an embodiment of the present disclosure.
- Figure 6 shows the results of confirming the formulation stability according to the temperature change of the emulsion composition according to an embodiment of the present specification.
- (a) is room temperature
- (b) is 37 ° C
- (c) is 45 ° C
- (d) is refrigerated
- (e) is the result of storage for 4 weeks under cycling conditions.
- Figure 7 shows the result of comparing the delivery effect of the potency component according to an experimental example of the present specification.
- Figure 8 shows the result of comparing the skin absorption amount of the potent component according to an experimental example of the present specification.
- FIG. 9A to 9d show the results of confirming the skin change in a dry environment after applying the composition to the skin according to an embodiment of the present disclosure.
- FIG. 9A shows changes in skin moisture content
- FIG. 9B shows changes in eye skin flexibility
- FIG. 9C shows changes in eye skin elasticity (R5)
- FIG. 9D shows changes in eye wrinkles (Ra).
- the techniques disclosed herein provide an emulsion composition comprising emulsion particles formed by an amphipathic nanocapsules.
- the technology disclosed herein provides an emulsifier composition for forming an emulsified particle comprising an amphiphilic nanocapsules as an active ingredient.
- the techniques disclosed herein provide an amphipathic nanocapsules for preparing an emulsion composition.
- the techniques disclosed herein provide for the use of an amphiphilic nanocapsule for preparing an emulsion composition.
- the techniques disclosed herein provide an amphiphilic nanocapsules for forming emulsion particles.
- the techniques disclosed herein provide for the use of an amphiphilic nanocapsules for forming emulsion particles.
- the technology disclosed herein provides an emulsification method comprising forming an emulsified particle with an amphiphilic nanocapsule.
- the emulsion composition may be one containing an emulsion particle.
- the emulsified particles may be surrounded by a plurality of aprotic nanocapsules.
- the emulsifying composition comprises an aqueous phase; And an oil phase, wherein two or more aprotic nanocapsules are positioned at an interface between the aqueous phase and the oil phase, and emulsion particles surrounded by the plurality of aprotic nanocapsules may be formed.
- the emulsification method comprises the steps of placing a plurality of aprotic nanocapsules at the water and oil phase interface; And forming an emulsion particle surrounded by the aprotic nanocapsule.
- the emulsifier composition may be an aqueous dispersion containing an aprotic nanocapsule as a water dispersion.
- the emulsion composition may not be emulsified with a surfactant.
- the plurality of aprotic nanocapsules may be attached to each other at the interface between the water phase and the oil phase to form emulsion particles.
- an amphiphilic nanocapsule means a nanocapsule which is not amphiphilic, and means that the physical properties of the nanocapsule are not amphiphilic having both a hydrophilic portion and a hydrophobic portion.
- the nanocapsules according to the present specification may be formed by an amphiphilic material such as phospholipid, but the physical properties of the formed nanocapsules themselves do not have amphiphilic properties. Therefore, it is not necessary to modify the physical properties to have a Janus structure, and unlike the emulsion composition using the Janus structure powder, it is possible to use without being limited to the physical properties of the oil phase.
- the nanocapsules according to the present disclosure may increase the safety for the skin by not using polyethylene glycol (PEG).
- the nanocapsule refers to a particle having a size in nano units, and the nanocapsule may have no distinction between an inner layer and an outer layer, or may have two or more layered structures.
- the inner layer may support an ingredient such as whitening and antioxidant.
- the aprotic nanocapsule may have an amorphous, spherical or oval shape.
- the emulsion composition may be of oil-in-water type.
- the emulsion composition according to the present specification does not show oil separation during lyophilization and shows very good formulation stability.
- the emulsion composition is freezing at a temperature of -60 °C or below or -120 to -60 °C and then sublimation and removal of the water under reduced pressure to produce a dry product when the oil separation phenomenon is visually confirmed It may not appear.
- the lyophilization conditions may be a temperature of -120 to -100 °C or -120 to -110 °C.
- the lyophilization conditions may be a pressure of 1 to 100 mTorr, 1 to 50 mTorr, 10 to 80 mTorr or 20 to 40 mTorr.
- the aprotic nanocapsules may have an average particle size of 10 nm to 1 ⁇ m.
- the aprotic nanocapsules may have an average particle size of 500 nm or less.
- the aprotic nanocapsule may have a particle size of 10 to 500 nm on average.
- the emulsified particles may be one having an average particle size of 1 ⁇ m to 30 ⁇ m.
- the emulsified particles have an average of at least 1 ⁇ m, at least 2 ⁇ m, at least 3 ⁇ m, at least 4 ⁇ m, at least 5 ⁇ m, at least 6 ⁇ m, at least 7 ⁇ m, at least 8 ⁇ m, at least 9 ⁇ m, 10 At least 11 ⁇ m, at least 11 ⁇ m, at least 12 ⁇ m, at least 13 ⁇ m, at least 14 ⁇ m, or at least 15 ⁇ m and at most 30 ⁇ m, at most 29 ⁇ m, at most 28 ⁇ m, at most 27 ⁇ m, at most 26 ⁇ m, at most 25 ⁇ m, at 24 ⁇ m.
- the emulsified particles have an average of 2 ⁇ m to 30 ⁇ m, 5 ⁇ m to 30 ⁇ m, 2 ⁇ m to 20 ⁇ m, 5 ⁇ m to 20 ⁇ m, 2 ⁇ m to 10 ⁇ m, 5 ⁇ m to 10 ⁇ m, or 2 ⁇ m to 15 ⁇ m It may have a particle size.
- emulsified particles using a surfactant has a size of about 1 to 2 ⁇ m and coalescing between the emulsion particles occurs, whereas emulsified particles according to the present specification may have a size of 2 ⁇ m or more, in that the coalescence between the emulsion particles does not occur There is a difference.
- the particle size of the aprotic nanocapsules or the particle size of the emulsified particles may mean the diameter of the particles.
- the diameter may mean the longest diameter.
- the aprotic nanocapsule is selected from the group consisting of liposomes, polymersomes, nanoemulsion particles, and solid lipid nanoparticles (SLN). It may be one or more.
- the liposomes, polymersomes, nanoemulsion particles and solid lipid nanoparticles can be prepared and used according to conventional manufacturing methods known in the art.
- the aprotic nanocapsules are nanoemulsion particles, the nanoemulsion particles can carry a potent ingredient and the skin delivery function of the potent ingredient is very excellent.
- the aprotic nanocapsule may be used for forming an emulsion particle without modifying the physical properties of the nanocapsule, including one or more selected from the group consisting of phospholipids, waxes, butters, and ceramides.
- the phospholipid is at least one selected from the group consisting of hydrogenated lecithin, hydrogenated phosphatidylcholine, soybean phospholipid, hydrogenated lysophosphatidylcholine, hydrogenated lyso lecithin and unsaturated lecithin. It may be.
- the wax is candelilla wax, carnauba wax, ozokerite, ceresin wax, montan wax, microcrystalline wax, tribehenin, glyceryl behenate, glyceryl dibehenate, glyceryl tree It may be one or more selected from the group consisting of behenate, stearyl behenate and trihydroxystearin.
- the butter is shea butter, cocoa butter, almond butter, apricot butter, peach butter, cupu butter, pistachio butter, olive butter, aloe butter, vanilla butter, illi butter, camellia butter, babasu It may be one or more selected from the group consisting of butter, avocado butter, jojoba butter, cocum butter, cacao butter, mango butter, soy butter, grape seed butter, cocum butter, murmur butter and macadamia seed butter.
- the ceramide may be natural ceramides, synthetic ceramides or similar ceramides.
- the similar ceramide is a synthetic material similar in structure to the natural ceramide, and has characteristics similar to the skin protection action, moisture retention ability, etc. of the natural ceramide, and is not limited in kind.
- hydroxypropyl bispalmitamide MAI It may be that.
- the aprotic nanocapsule may be included in the aqueous phase of the emulsion composition in a form dispersed in an aqueous dispersion.
- the aqueous phase may include an aqueous dispersion including an aprotic nanocapsule, wherein the aprotic nanocapsule may be positioned at the water phase and the oil phase interface of the emulsion composition to form emulsion particles.
- the aprotic nanocapsules may be water-dispersible aprotic nanocapsules. Therefore, the emulsion composition according to the present specification is an aqueous phase comprising a water-dispersible aprotic nanocapsules; And an oil phase, and a plurality of aprotic nanocapsules may be to form emulsified particles.
- water-dispersion-type amphiphilic nanocapsules are meant to be non-amphiphilic nanocapsules present in a dispersed form in the aqueous phase. It may be.
- the emulsion composition may be an oil phase and an aqueous dispersion comprising an aprotic nanocapsules in a weight ratio of 1: 0.4 to 3. Accordingly, there is an effect of preventing the problem that the formulation stability is lowered because the content of the water-dispersion type amphiphilic nanocapsules is too small. In addition, there is a large amount of water-dispersion-type amphiphilic nanocapsule content is effective to prevent the problem that the feeling of use can be lowered because the spreadability, spreadability, low absorption.
- the water-dispersion-type amphiphilic nanocapsules ie, the aqueous dispersion including the amphipathic nanocapsules
- added to and mixed with the aqueous phase of the emulsion composition may be water, a polyhydric alcohol, and a lipid. have.
- the water-dispersion-type amphiphilic nanocapsules added to and mixed with the aqueous phase of the emulsifying composition may be formed in the water phase part with respect to the total weight of the aqueous dispersion. To 90 weight percent; And it may be to include 1 to 55% by weight of the oil phase including the lipid.
- the lipid may be 1 to 30% by weight based on the total weight of the aqueous dispersion. In another exemplary embodiment, the lipid is 1% by weight, 3% by weight, 5% by weight, 7% by weight, 9% by weight, 11% by weight, 13% by weight based on the total weight of the aqueous dispersion. It may include at least 30% by weight, at least 15% by weight, at most 28% by weight, at most 26% by weight, at most 24%, at most 22%, or at most 20% by weight.
- the water phase part may be a polyhydric alcohol.
- the oil phase portion may include one or more selected from the group consisting of polyhydric alcohols, emulsifiers and oils.
- the water-dispersion-type amphiphilic nanocapsules ie, the aqueous dispersion including the amphipathic nanocapsules
- added to and mixed with the aqueous phase of the emulsion composition may include 45-75 wt% of the water phase; And 25 to 55 wt% of an oil phase including a polyhydric alcohol, a lipid, and an emulsifier.
- the polyhydric alcohol, lipids and emulsifiers are preferably mixed in an amount of 40 to 55%, 30 to 50% and 10 to 20% by weight based on the total weight of the oil phase, respectively. Can be.
- the lipids include phospholipids and waxes, and it may be desirable for the phospholipids and waxes to be mixed in a weight ratio of 1: 9 to 18 in terms of emulsion formation and formulation stability.
- the lipid may further include ceramide, and the ceramide may be mixed with phospholipid in a weight ratio of 1: 3 to 3: 1.
- the water-dispersion-type amphiphilic nanocapsules added to and mixed with the water phase of the emulsion composition may include a water-phase portion 70 to 90 including a polyhydric alcohol. weight%; And it may be to include 10 to 30% by weight of the oil phase including the oil and lipids.
- the lipid may be one or more selected from the group consisting of phospholipids, waxes, butters and ceramides.
- the polyhydric alcohol may be one or more selected from the group consisting of butylene glycol, propylene glycol, glycerin, pentylene glycol, dipropylene glycol and diglycerin.
- the emulsifier is sorbitan sesquioleate, glyceryl stearate, polysorbate 60, polysorbate 80, sorbitan stearate, PEG-20 glyceryl isostearate, polyglyceryl- 2 diisostearate, cetearyl alcohol, polyglyceryl-3 methylglucose distearate, PEG-100 stearate, sorbitan isostearate, lauryl glucoside, disodium coco ampodiacetate, coconut fatty acid diethanolamide And cocoamidopropyl betaine may be one or more selected from the group consisting of.
- the oil may be at least one selected from the group consisting of vegetable oils, silicone oils, ester oils and hydrocarbon oils.
- the vegetable oil is olive oil, camellia oil, castor oil, jojoba oil, almond oil, grape seed oil, herbal oil, rose oil, coconut oil, avocado oil, macadamia oil, moringa oil, rice bran oil It may be one or more selected from the group consisting of apricot seed oil, sunflower oil, meadowfoam seed oil and abyssinian oil.
- the silicone oil may be at least one selected from the group consisting of dimethylpolysiloxane, methylphenylpolysiloxane, decamethylcyclopentasiloxane, methyltrimethicone, phenyltrimethicone, cyclomethicone and dimethicone. .
- the ester oil is isopropyl palmitate, 2-octyldodecyl myristate, isopropyl myristate, butyloctyl salicylate, cetyloctanoate, cetyl octyl hexanoate, cococapryl It may be one or more selected from the group consisting of laterate / caprate, decyl cocoate, isostearyl isostearate, pentaerythritol tetraethylhexanoate, dicaprylylcarbonate.
- the hydrocarbon-based oil is n-octane, n-nonane, n-decane, n-undecane, n-dodecane, n-tridecane, n-tetradecane, n-pentadecane, n-hexadecane, n-heptadecane, n-octadecane, petrolatum, paraffin, ceresin, hydrogenated polydecene, hydrogenated polyisobutene and squalane may be one or more selected from the group consisting of.
- the technology disclosed herein is a method for preparing the water-dispersion-type amphiphilic nanocapsules comprising the steps of mixing and dissolving the water phase; Mixing and dissolving the oil phase; And it provides a method of producing a water-dispersion-type amphiphilic nanocapsules comprising the step of adding the oil phase to the water phase portion and dispersed with a homogenizer and then cooled.
- the homogenizer may be used without any limitation as long as it provides a sufficient energy to disperse the molten lipophilic mixture phase to prepare the nanocapsules in a particle size of 10 nm to 1 ⁇ m.
- ultrasonic and high pressure homogenizers may be preferred to form nanocapsule particles of lipids.
- the emulsion composition does not further use a surfactant for emulsification of the emulsion composition in addition to the surfactant used in the preparation of the nanocapsules. Therefore, since the switching with the surfactant present in the outer phase of the emulsion composition can maintain the stability of the nanocapsule in the formulation, the stability of the emulsion particle structure for a longer time. Accordingly, the emulsion composition is very excellent in formulation stability against cold thaw. In addition, the water-dispersion-type amphiphilic nanocapsules are easy to mass production has the effect of improving the disadvantages of the emulsification method to stabilize the conventional powder on the interface.
- Nanocapsules present at the interface are packed on the surface of the skin to improve the roughness of the skin and at the same time, inhibit the evaporation of water by an occlusive effect, thereby increasing the skin moisture content. It is effective to maintain.
- the agonist component in the aprotic amphiphilic nanocapsules it is possible to improve the skin delivery power of the agonist.
- Nanocapsules according to the present specification can be designed in various ways depending on the purpose, such as feeling, efficacy.
- the technology disclosed herein is a method for preparing the emulsion composition, comprising the steps of mixing an aqueous phase and an oil phase comprising a water-dispersible aprotic nanocapsules; And attaching the aprotic nanocapsules to each other to form emulsified particles surrounded by the aprotic nanocapsules.
- composition (wt%) of Tables 1 and 2 to prepare a water-dispersible aprotic nanocapsules.
- the oil phase was heated and dissolved at 70 ° C. and then dispersed with a homogenizer to prepare a lipophilic mixture.
- the lipophilic mixture prepared above was slowly added to the aqueous phase to form capsule particles through a homogenizer at 70 ° C. Cooling it causes recrystallization of lipids and nanocapsule particles are formed.
- Example 1-1 Formation of solid lipid nanoparticles (Example 1-1) and nanoemulsion particles (Example 1-2) by preparing nanocapsules with a particle size of 10 nm to 1 ⁇ m using an ultrasonic and high pressure homogenizer as a homogenizer A water-dispersion-type amphiphilic nanocapsules were prepared.
- Example 1-1 awards WATER To 100 1,2-hexanediol (1,2-HEXANDIOL) One Ethylhexylglycerine (ETHYLHEXYLGLYCERIN) 0.05 Paid Butylene glycol (BUTYLENE GLYCOL) 20 Hydroxypropyl bispalmitamide MEI (HYDROXYPROPYL BISPALMITAMIDE MEA) One Polyglyceryl-3 Methylglucose Distearate (POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE) 7 HYDROGENATED LECITHIN One Stearyl behenate 13
- Example 1-2 awards WATER To 100 Ethylhexylglycerine (ETHYLHEXYLGLYCERIN) 0.05 1,2-hexanediol (1,2-HEXANDIOL) 1.5 Butylene glycol (BUTYLENE GLYCOL) 10 Paid MADE FOAM SEED OIL 6.0 Ceramide 3 1.0 Cholesterol (CHOLESTEROL) 1.0 STEARIC ACID * PALMITIC ACID 0.8 HYDROGENATED LECITHIN 3 Shea Butter 5.5 Tocopherol (TOCOPHEROL) 0.5
- an emulsion composition was prepared as follows.
- aqueous phase comprising water, water-dispersible aprotic nanocapsules, 1,2-hexanediol, ethylhexylglycerine, carbomer and tromethamine was warmed to 50-75 ° C. to mix and dissolve.
- Example 11 Comparative Example 1 SQUALANE 10 10 HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 Hydrogenated C6-14 Olefin Polymer (HYDROGENATED C6-14 OLEFIN POLYMERS) 10 5 2 10 10 10 10 10 10 10 10 Pentaerythrityl Tetraethylhexanoate 10 10 DICAPRYLYL CARBONATE * TOCOPHEROL * GLYCINE SOJA (SOYBEAN) OIL 10 Cyclopentasiloxane * cyclohexasiloxane (CYCLOPENTASILOXANE * CYCLOHEXASILOXANE) 2 2 2 2 2 2 2 2 2 2 2 2 WATER To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 Water Disper
- Example 2 Example 3
- Example 4 Example 5
- Example 6 Example 7
- Example 9 Example 10 Comparative Example 1 Spreadability when applied ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Application when applied ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Moisturizing Persistence ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Absorption ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Formulation Stability ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- Example 2 3 7 and Comparative Example 1 as a result of confirming the formulation stability according to the content of the water-dispersion type non-ambiophilic nanocapsules and the oil content, as the oil content increases the ratio to be located at the interface between water and oil Increasing the content of amphiphilic nanocapsules was also desirable in terms of formulation stability.
- the lack of moisturizing persistence and absorptiveness in Example 7 seems to be due to the relatively low content of oil and amphiphilic nanocapsules.
- a fluorescent dye (nile red, 515-560 nm excitation;> 590 nm emission) was added to prepare the nanocapsules in the same manner as in Example 1-1.
- a fluorescent dye nile red, 515-560 nm excitation;> 590 nm emission
- FIG. 1A shows an image observed with a polarizing microscope (LV100POL), and FIG. 1B shows an image observed with a laser confocal microscope (VIVASCOPE 1500). It was found that the nanocapsules loaded with fluorescent dye were located at the emulsion particle interface. Emulsifying composition according to the present specification was found to be able to form the emulsion particles by stabilizing the nanocapsules in the aqueous and oil phase interface without the use of a surfactant.
- compositions of Examples 2 and 11 were found to have distinctive features in structure and usability compared to conventional emulsion formulations.
- the O / W emulsion and the pickling emulsion were prepared as follows and used for the experiment.
- a pickling emulsion was prepared according to a conventional method according to the composition (wt%) of Table 6 below.
- Example 2 The emulsified composition of Example 2 prepared above was applied to the skin to observe the change in skin texture and moisture content.
- Example 2 prepared above and the O / W emulsion of Experimental Example 3 were lyophilized to compare their formulation stability.
- Freeze-drying is a type of drying method, in which a dry product is produced by a sublimation process in which ice is directly vaporized by freezing the material and lowering the partial pressure of water vapor.
- the emulsion composition of Example 2 and the O / W emulsion of Experimental Example 3 were first frozen at a temperature of ⁇ 80 ° C. or lower using a freezer, and then transferred to a drier, followed by sublimation to FIG. 5 (left: O / W emulsion of Experimental Example 3). , Right: A lyophilized sample as in the emulsion composition of Example 2) was obtained.
- Such lyophilization has the advantage that it can be used in various forms of cosmetics and stabilization of the efficacy of the component according to the purpose by reprocessing in the form of powder to rehydrate at the use stage.
- emulsions such as the O / W emulsion of Experimental Example 3 is the shrinkage of the appearance during the freeze-drying process is deformed due to the deformation of the oil occurs freeze-drying, whereas the freeze-dried emulsion composition of Example 2 is oil It was confirmed that the emulsion particle structure was well maintained without this separation phenomenon and had excellent formulation stability. In general emulsions, other efforts are required to maintain the emulsion particle structure well, which may result in unexpected feelings. However, when using the nanocapsules according to the present specification, since the emulsion particles are well packed by the nanocapsules and maintain their structure, it is possible to realize formulation stability without using additional materials and to have excellent feeling of use.
- the formulation stability of the emulsion composition of Example 2 prepared above was observed in accordance with the temperature change is shown in Figure 6. As a result, it was confirmed that the formulation stability was maintained when stored for 4 weeks at room temperature, 37 °C, 45 °C, refrigerated conditions. In addition, maintaining the stability of the formulation without separation of oil during cycling storage for a total of 12 weeks for a total of four weeks by applying a temperature change from 40 °C to -10 °C, or from -10 °C to 40 °C over 12 hours Confirmed.
- the delivery effect of tocopherol as an efficacy ingredient in the nanocapsules of the emulsion composition of Example 11 was confirmed and shown in FIG. 7.
- the delivery effect of the potent ingredient was compared with the O / W emulsion prepared by adding 0.5% by weight of tocopherol to the O / W emulsion of Experimental Example 3.
- Example 11 delivers the active ingredient more deeply into the skin than the O / W emulsion of Experimental Example 3 to which tocopherol was added.
- the light yellow part represents the potency ingredient.
- the skin absorption amount of tocopherol which is an efficacy ingredient in the nanocapsules of the emulsion composition of Example 11, was confirmed and shown in FIG. 8.
- the skin absorption of the potent ingredient was compared with the O / W emulsion prepared by adding 0.5% by weight of tocopherol to the O / W emulsion of Experimental Example 3.
- Example 11 had a higher skin absorption amount of tocopherol than the O / W emulsion of Experimental Example 3 to which tocopherol was added.
- 1 to 5 tapes, 6 to 10 tapes, and 1 to 10 tapes represent average values of tapes 1 to 5, average values of tapes 6 to 10, and average values of tapes 1 to 10, respectively.
- the measured absorption (%) is shown.
- Example 11 After applying the emulsified composition of Example 11 to the skin, the skin moisture content, eye skin flexibility, eye skin elasticity, and eye wrinkle change in a dry environment were confirmed and shown in FIGS. 9A to 9D.
- the drying environment was achieved by waiting for 1 hour under conditions of less than 35% relative humidity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
실시예 1-1 | ||
수상 | 물(WATER) | To 100 |
1,2-헥산디올(1,2-HEXANDIOL) | 1 | |
에틸헥실글리세린(ETHYLHEXYLGLYCERIN) | 0.05 | |
유상 | 부틸렌 글라이콜(BUTYLENE GLYCOL) | 20 |
하이드록시프로필 비스팔미타마이드 엠이에이(HYDROXYPROPYL BISPALMITAMIDE MEA) | 1 | |
폴리글리세릴-3 메틸글루코오스 디스테아레이트(POLYGLYCERYL-3 METHYLGLUCOSE DISTEARATE) | 7 | |
하이드로제네이티드 레시틴(HYDROGENATED LECITHIN) | 1 | |
스테아릴 베헤네이트(STEARYL BEHENATE) | 13 |
실시예 1-2 | ||
수상 | 물(WATER) | To 100 |
에틸헥실글리세린(ETHYLHEXYLGLYCERIN) | 0.05 | |
1,2-헥산디올(1,2-HEXANDIOL) | 1.5 | |
부틸렌 글라이콜(BUTYLENE GLYCOL) | 10 | |
유상 | 메드폼시드오일(MEADOWFOAM SEED OIL) | 6.0 |
세라마이드 3(CERAMIDE 3) | 1.0 | |
콜레스테롤(CHOLESTEROL) | 1.0 | |
스테아릭애씨드*팔미틱애씨드(STEARIC ACID*PALMITIC ACID) | 0.8 | |
하이드로제네이티드 레시틴(HYDROGENATED LECITHIN) | 3 | |
쉐어버터(SHEA BUTTER) | 5.5 | |
토코페롤(TOCOPHEROL) | 0.5 |
INCI | 실시예2 | 실시예3 | 실시예4 | 실시예5 | 실시예6 | 실시예7 | 실시예8 | 실시예9 | 실시예10 | 실시예 11 | 비교예1 |
스쿠알란(SQUALANE) | 10 | 10 | |||||||||
해바라기씨오일(HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
하이드로제네이티드 C6-14 올레핀 폴리머(HYDROGENATED C6-14 OLEFIN POLYMERS) | 10 | 5 | 2 | 10 | 10 | 10 | 10 | 10 | |||
펜타에리스리틸 테트라에틸헥사노에이트(Pentaerythrityl Tetraethylhexanoate) | 10 | 10 | |||||||||
디카프릴릴 카보네이트*토코페놀*돌콩오일(DICAPRYLYL CARBONATE*TOCOPHEROL*GLYCINE SOJA (SOYBEAN) OIL) | 10 | ||||||||||
사이클로펜타실록산*사이클로헥사실록산(CYCLOPENTASILOXANE*CYCLOHEXASILOXANE) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
물(WATER) | To 100 | To 100 | To 100 | To 100 | To 100 | To 100 | To 100 | To 100 | To 100 | To 100 | To 100 |
실시예 1-1의 수분산형 비양친매성 나노캡슐 | 10 | 50 | 10 | 10 | 10 | 5 | 20 | 30 | 40 | 5 | |
실시예 1-2의 수분산형 비양친매성 나노캡슐 | 10 | ||||||||||
1,2-헥산디올(1,2-HEXANEDIOL) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
에틸헥실글리세린(ETHYLHEXYLGLYCERIN) | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
카보머(CARBOMER) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
트로메타민(TROMETHAMINE) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
실시예2 | 실시예3 | 실시예4 | 실시예5 | 실시예6 | 실시예7 | 실시예8 | 실시예9 | 실시예10 | 비교예1 | |
도포 시 퍼짐성 | ◎ | ○ | ◎ | ◎ | ◎ | ◎ | ◎ | ◎ | ○ | ◎ |
도포 시 발림성 | ◎ | ○ | ◎ | ◎ | ◎ | ◎ | ◎ | ◎ | ○ | ◎ |
보습감 지속성 | ◎ | ◎ | ◎ | ◎ | △ | △ | ◎ | ◎ | ◎ | ○ |
흡수감 | ◎ | ◎ | ◎ | ◎ | ○ | △ | ◎ | ◎ | ◎ | △ |
제형 안정도 | ◎ | ◎ | ◎ | ◎ | ◎ | ◎ | ◎ | ◎ | ◎ | △ |
INCI | 함량 |
피이지-100스테아레이트*글리세릴스테아레이트 | 5.00 |
스쿠알란 | 7.00 |
디이소스테아릴말레이트 | 5.00 |
디메치콘 | 4.00 |
정제수 | To 100 |
디소듐이디티에이 | 0.05 |
글리세린 | 0.50 |
글리세릴카프릴레이트 | 0.10 |
에틸헥실글리세린 | 0.05 |
베헤닐알코올 | 2.00 |
향료 | 0.05 |
정제수*소르비탄이소스테아레이트*폴리아크릴레이트-13*폴리이소부텐*폴리소르베이트20 | 0.43 |
INCI | 함량 |
정제수 | To 100 |
디소듐이디티에이 | 0.05 |
부틸렌글라이콜 | 10.00 |
페녹시에탄올 | 0.20 |
에틸헥실글리세린 | 0.05 |
C12-15알킬벤조에이트 | 5.00 |
에틸헥실메톡시신나메이트 | 3.00 |
비스-에틸헥실옥시페놀메톡시페닐트리아진 | 3.00 |
사이클로펜타실록산*사이클로헥사실록산 | 5.00 |
실리카 | 2.00 |
티타늄디옥사이드*스테아릭애씨드*알루미나 | 2.00 |
향료 | 0.25 |
정제수*소르비탄이소스테아레이트*폴리아크릴레이트-13*폴리이소부텐*폴리소르베이트20 | 1.00 |
경시변화(점도) | |
실시예2 | |
제조직후 | 12500 cps |
1주후 | 14800 cps |
2주후 | 15600 cps |
3주후 | 14500 cps |
4주후 | 15300 cps |
Claims (12)
- 수상; 및유상을 포함하고,상기 수상과 유상 계면에 다수의 비양친매성 나노캡슐이 위치하고,상기 다수의 비양친매성 나노캡슐에 의해 둘러싸인 유화입자가 형성된 유화 조성물.
- 제 1항에 있어서,상기 유화 조성물은 수중유형인 것인, 유화 조성물.
- 제 1항에 있어서,상기 유화 조성물은, -60 ℃ 이하의 온도에서 동결시킨 다음 감압하여 물을 승화 및 제거하여 건조물로 제조할 때 오일분리현상이 나타나지 않는 것인, 유화 조성물.
- 제 1항에 있어서,상기 비양친매성 나노캡슐은 평균 10 nm 내지 1 ㎛의 입자 크기를 갖는 것인, 유화 조성물.
- 제 1항에 있어서,상기 유화입자는 평균 1 ㎛ 내지 30 ㎛의 입자 크기를 갖는 것인, 유화 조성물.
- 제 1항에 있어서,상기 비양친매성 나노캡슐은 리포좀 (Liposome), 폴리머좀 (Polymersome), 나노에멀젼 입자 (Nanoemulsion Particle) 및 고체 지질 나노입자 (Solid Lipid Nanoparticle, SLN)로 이루어진 군에서 선택되는 1 이상인 것인, 유화 조성물.
- 제 1항에 있어서,상기 비양친매성 나노캡슐은 인지질, 왁스, 버터 및 세라마이드로 이루어진 군에서 선택되는 1 이상을 포함하는 것인, 유화 조성물.
- 제 1항에 있어서,상기 비양친매성 나노캡슐은 수분산액에 분산된 형태로 유화 조성물의 수상에 포함되는 것인, 유화 조성물.
- 제 8항에 있어서,상기 유화 조성물은 유상 : 비양친매성 나노캡슐을 포함하는 수분산액의 혼합 중량비가 1 : 0.4 내지 3인 것인, 유화 조성물.
- 제 8항에 있어서,상기 비양친매성 나노캡슐을 포함하는 수분산액은 물, 다가 알코올 및 지질을 포함하는 것인, 유화 조성물.
- 제 10항에 있어서,상기 지질은 인지질, 왁스, 버터 및 세라마이드로 이루어진 군에서 선택되는 1 이상인 것인, 유화 조성물.
- 제 1항 내지 제 11항 중 어느 한 항의 유화 조성물을 제조하는 방법으로,수분산형 비양친매성 나노캡슐을 포함하는 수상과, 유상을 혼합하는 단계; 및상기 비양친매성 나노캡슐에 의해 둘러싸인 유화입자를 형성하는 단계를 포함하는 유화 조성물의 제조방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980056910.2A CN112638351A (zh) | 2018-08-31 | 2019-08-28 | 形成乳化颗粒的纳米胶囊及包含其的乳化组合物 |
CA3110333A CA3110333A1 (en) | 2018-08-31 | 2019-08-28 | Nanocapsules forming emulsion particles and emulsion composition including same |
SG11202101570VA SG11202101570VA (en) | 2018-08-31 | 2019-08-28 | Nanocapsules forming emulsion particles and emulsion composition including same |
AU2019329653A AU2019329653A1 (en) | 2018-08-31 | 2019-08-28 | Nanocapsules forming emulsion particles and emulsion composition including same |
US17/268,156 US20210299008A1 (en) | 2018-08-31 | 2019-08-28 | Nanocapsules forming emulsion particles and emulsion composition including same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180103955 | 2018-08-31 | ||
KR10-2018-0103955 | 2018-08-31 | ||
KR10-2019-0102837 | 2019-08-22 | ||
KR1020190102837A KR102610938B1 (ko) | 2018-08-31 | 2019-08-22 | 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020045983A1 true WO2020045983A1 (ko) | 2020-03-05 |
Family
ID=69644434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/011001 WO2020045983A1 (ko) | 2018-08-31 | 2019-08-28 | 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020045983A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040084364A (ko) * | 2003-03-28 | 2004-10-06 | 주식회사 태평양 | 폴리올/고분자 마이크로캡슐을 이용한 유효성분 안정화방법 및 이를 함유하는 화장료 조성물 |
KR20070042298A (ko) * | 2005-10-18 | 2007-04-23 | (주)아모레퍼시픽 | 유용성 활성물질 안정화 양이온성 고분자 나노캡슐 및 이의제조방법, 및 이를 함유하는 화장료 조성물 |
KR20070089358A (ko) * | 2006-02-28 | 2007-08-31 | (주)아모레퍼시픽 | 수분산성 고분자 나노캡슐 및 이의 제조 방법, 및 이를함유하는 피부외용제 조성물 |
KR101547528B1 (ko) * | 2014-01-08 | 2015-08-26 | 주식회사 코스메카코리아 | 유중수형 피커링 에멀젼 화장료 조성물 및 이의 제조방법 |
WO2018105747A1 (ja) * | 2016-12-08 | 2018-06-14 | 三菱ケミカルフーズ株式会社 | 水中油型乳化組成物、及び該水中油型乳化組成物の製造方法 |
US20180200689A1 (en) * | 2015-07-30 | 2018-07-19 | Dwi-Leibniz-Institut Für Interaktive Materialien E.V. | Method for the encapsulation of substances in silica-based capsules and the products obtained thereof |
-
2019
- 2019-08-28 WO PCT/KR2019/011001 patent/WO2020045983A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040084364A (ko) * | 2003-03-28 | 2004-10-06 | 주식회사 태평양 | 폴리올/고분자 마이크로캡슐을 이용한 유효성분 안정화방법 및 이를 함유하는 화장료 조성물 |
KR20070042298A (ko) * | 2005-10-18 | 2007-04-23 | (주)아모레퍼시픽 | 유용성 활성물질 안정화 양이온성 고분자 나노캡슐 및 이의제조방법, 및 이를 함유하는 화장료 조성물 |
KR20070089358A (ko) * | 2006-02-28 | 2007-08-31 | (주)아모레퍼시픽 | 수분산성 고분자 나노캡슐 및 이의 제조 방법, 및 이를함유하는 피부외용제 조성물 |
KR101547528B1 (ko) * | 2014-01-08 | 2015-08-26 | 주식회사 코스메카코리아 | 유중수형 피커링 에멀젼 화장료 조성물 및 이의 제조방법 |
US20180200689A1 (en) * | 2015-07-30 | 2018-07-19 | Dwi-Leibniz-Institut Für Interaktive Materialien E.V. | Method for the encapsulation of substances in silica-based capsules and the products obtained thereof |
WO2018105747A1 (ja) * | 2016-12-08 | 2018-06-14 | 三菱ケミカルフーズ株式会社 | 水中油型乳化組成物、及び該水中油型乳化組成物の製造方法 |
Non-Patent Citations (1)
Title |
---|
HU , Z.: "Surfactant-enhanced cellulose nanocrystal pickering emulsions", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 439, 2015, pages 139 - 148, XP055231305, DOI: 10.1016/j.jcis.2014.10.034 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013039350A2 (ko) | 세라마이드를 포함하는 피부 외용제 조성물 | |
US5804216A (en) | Acidic composition based on lipid vesicles and its use in topical application | |
WO2020116892A2 (ko) | 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법 | |
EP1347734B2 (de) | Vesikelbildende hautöle enthaltend w/o-emulgatoren mit einem hlb-wert von 2-5,9, herstellungsverfahren und verwendung | |
US6379681B1 (en) | Oil-in-water emulsions for reconstituting lamellarity of the lipid structure of damaged skin | |
WO2015012424A1 (ko) | 오르가노겔 조성물 및 이를 이용하여 제조된 오르가노겔 마스크 팩 | |
WO2017175981A1 (ko) | 주름 은폐용 화장료 조성물 | |
WO2022092550A1 (ko) | 수분감이 극대화된 유중수형 화장료 조성물 | |
US5756014A (en) | Heat resistant lipid vesicles | |
WO2020105840A1 (ko) | 난용성 성분 안정화용 조성물 및 이를 포함하는 화장료 조성물 | |
WO2020145495A1 (ko) | 수용성 추출물이 흡수된 화장용 캡슐을 포함하는 화장료 조성물 | |
WO2020045983A1 (ko) | 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물 | |
WO2017003129A1 (ko) | 라멜라 구조체를 포함하는 메이크업 화장료 조성물 | |
WO2021172908A1 (ko) | 사용감이 개선된 조성물 | |
WO2019098746A2 (ko) | 투명한 화장료 조성물 | |
KR20200026070A (ko) | 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물 | |
WO2023239201A1 (ko) | 자외선 차단 효율 상승효과를 갖는 유기 자외선 차단제 캡슐 | |
WO2018004247A1 (ko) | 고융점 왁스를 포함하는 수중유형 화장료 조성물 | |
WO2019177187A1 (en) | Method of manufacturing composition material for skin moisturizing containing vehicle having multi-layer globule | |
WO2019194560A1 (ko) | 난용성 물질을 포함하는 화장료 및 그의 제조방법 | |
WO2019172468A1 (en) | Method of manufacturing dermatologically active substance vehicle having multi-layer structure, and composition material for functional cosmetic containing dermatologically active substance vehicle manufactured using the same | |
KR20210119781A (ko) | 유중수형(w/o) 라멜라 액정 에멀젼 화장료 조성물 | |
WO2016199976A1 (ko) | 다릅나무 추출물을 유효성분으로 함유한 피부주름개선용 화장료 조성물 및 그를 이용한 화장료 | |
KR20110076076A (ko) | 라멜라 액정이 수분산된 실리콘 중 수(w/s) 타입 유화 조성물 및 이의 용도 | |
WO2023033414A1 (ko) | 유효 성분의 포집력이 우수한 리포좀 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19854241 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3110333 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2101001088 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019329653 Country of ref document: AU Date of ref document: 20190828 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19854241 Country of ref document: EP Kind code of ref document: A1 |